FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788392735> ?p ?o ?g. }

• W2788392735 endingPage "e64" @default.
• W2788392735 startingPage "656" @default.
• W2788392735 abstract "Abstract Lessons Learned In abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) patients, selinexor led to prostate-specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication. Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population. This study highlights the challenge of primary endpoint selection for phase II studies in the post-abiraterone and/or post-enzalutamide mCRPC space. Background Selinexor is a first-in-class selective inhibitor of nuclear export compound that specifically inhibits the nuclear export protein Exportin-1 (XPO-1), leading to nuclear accumulation of tumor suppressor proteins. Methods This phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone and/or enzalutamide. Results Fourteen patients were enrolled. Selinexor was initially administered at 65 mg/m2 twice a week (days 1 and 3) and was subsequently reduced to 60 mg flat dose twice a week (days 1 and 3), 3 weeks on, 1 week off, to improve tolerability. The median treatment duration was 13 weeks. At a median follow-up of 4 months, two patients (14%) had ≥50% prostate-specific antigen (PSA) decline, and seven patients (50%) had any PSA decline. Of eight patients with measurable disease at baseline, two (25%) had a partial response and four (50%) had stable disease as their best radiographic response. Five patients (36%) experienced serious adverse events (SAEs; all unrelated to selinexor), and five patients (36%) experienced treatment-related grade 3–4 AEs. The most common drug-related adverse events (AEs) of any severity were anorexia, nausea, weight loss, fatigue, and thrombocytopenia. Three patients (21%) came off study for unacceptable tolerability. Conclusion Selinexor demonstrated clinical activity and poor tolerability in mCRPC patients refractory to second-line anti-androgenic agents." @default.
• W2788392735 created "2018-03-06" @default.
• W2788392735 creator A5012804612 @default.
• W2788392735 creator A5019669804 @default.
• W2788392735 creator A5024203592 @default.
• W2788392735 creator A5043368519 @default.
• W2788392735 creator A5044358201 @default.
• W2788392735 creator A5046056541 @default.
• W2788392735 creator A5066716873 @default.
• W2788392735 creator A5073970384 @default.
• W2788392735 creator A5079570071 @default.
• W2788392735 creator A5081123075 @default.
• W2788392735 creator A5086477978 @default.
• W2788392735 date "2018-02-27" @default.
• W2788392735 modified "2023-09-29" @default.
• W2788392735 title "A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer" @default.
• W2788392735 cites W1544524487 @default.
• W2788392735 cites W1560279371 @default.
• W2788392735 cites W1562998360 @default.
• W2788392735 cites W1844925317 @default.
• W2788392735 cites W2009975411 @default.
• W2788392735 cites W2028885314 @default.
• W2788392735 cites W2110534364 @default.
• W2788392735 cites W2137467802 @default.
• W2788392735 cites W2148643283 @default.
• W2788392735 cites W2166918329 @default.
• W2788392735 cites W2169669596 @default.
• W2788392735 cites W2187721367 @default.
• W2788392735 cites W2290633618 @default.
• W2788392735 cites W2400101856 @default.
• W2788392735 cites W2402183197 @default.
• W2788392735 cites W2419426348 @default.
• W2788392735 cites W2495597122 @default.
• W2788392735 cites W2520937393 @default.
• W2788392735 cites W2533094307 @default.
• W2788392735 cites W2588817137 @default.
• W2788392735 cites W2610540653 @default.
• W2788392735 cites W2622862433 @default.
• W2788392735 doi "https://doi.org/10.1634/theoncologist.2017-0624" @default.
• W2788392735 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6067936" @default.
• W2788392735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29487219" @default.
• W2788392735 hasPublicationYear "2018" @default.
• W2788392735 type Work @default.
• W2788392735 sameAs 2788392735 @default.
• W2788392735 citedByCount "21" @default.
• W2788392735 countsByYear W27883927352018 @default.
• W2788392735 countsByYear W27883927352019 @default.
• W2788392735 countsByYear W27883927352020 @default.
• W2788392735 countsByYear W27883927352021 @default.
• W2788392735 countsByYear W27883927352022 @default.
• W2788392735 countsByYear W27883927352023 @default.
• W2788392735 crossrefType "journal-article" @default.
• W2788392735 hasAuthorship W2788392735A5012804612 @default.
• W2788392735 hasAuthorship W2788392735A5019669804 @default.
• W2788392735 hasAuthorship W2788392735A5024203592 @default.
• W2788392735 hasAuthorship W2788392735A5043368519 @default.
• W2788392735 hasAuthorship W2788392735A5044358201 @default.
• W2788392735 hasAuthorship W2788392735A5046056541 @default.
• W2788392735 hasAuthorship W2788392735A5066716873 @default.
• W2788392735 hasAuthorship W2788392735A5073970384 @default.
• W2788392735 hasAuthorship W2788392735A5079570071 @default.
• W2788392735 hasAuthorship W2788392735A5081123075 @default.
• W2788392735 hasAuthorship W2788392735A5086477978 @default.
• W2788392735 hasBestOaLocation W27883927351 @default.
• W2788392735 hasConcept C121332964 @default.
• W2788392735 hasConcept C121608353 @default.
• W2788392735 hasConcept C126322002 @default.
• W2788392735 hasConcept C142424586 @default.
• W2788392735 hasConcept C143998085 @default.
• W2788392735 hasConcept C197934379 @default.
• W2788392735 hasConcept C203092338 @default.
• W2788392735 hasConcept C2776551883 @default.
• W2788392735 hasConcept C2777899217 @default.
• W2788392735 hasConcept C2778375690 @default.
• W2788392735 hasConcept C2780192828 @default.
• W2788392735 hasConcept C2908647359 @default.
• W2788392735 hasConcept C31760486 @default.
• W2788392735 hasConcept C535046627 @default.
• W2788392735 hasConcept C61367390 @default.
• W2788392735 hasConcept C71924100 @default.
• W2788392735 hasConcept C87355193 @default.
• W2788392735 hasConcept C98274493 @default.
• W2788392735 hasConcept C99454951 @default.
• W2788392735 hasConceptScore W2788392735C121332964 @default.
• W2788392735 hasConceptScore W2788392735C121608353 @default.
• W2788392735 hasConceptScore W2788392735C126322002 @default.
• W2788392735 hasConceptScore W2788392735C142424586 @default.
• W2788392735 hasConceptScore W2788392735C143998085 @default.
• W2788392735 hasConceptScore W2788392735C197934379 @default.
• W2788392735 hasConceptScore W2788392735C203092338 @default.
• W2788392735 hasConceptScore W2788392735C2776551883 @default.
• W2788392735 hasConceptScore W2788392735C2777899217 @default.
• W2788392735 hasConceptScore W2788392735C2778375690 @default.
• W2788392735 hasConceptScore W2788392735C2780192828 @default.
• W2788392735 hasConceptScore W2788392735C2908647359 @default.
• W2788392735 hasConceptScore W2788392735C31760486 @default.
• W2788392735 hasConceptScore W2788392735C535046627 @default.
• W2788392735 hasConceptScore W2788392735C61367390 @default.

• next